Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Blue Light Cystoscopy With Cysview® Registry

NCT02660645 · View on ClinicalTrials.gov ↗

Study Summary

Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

Conditions Studied

Interventions

  • DEVICE Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
  • DRUG Hexaminolevulinate hydrochloride (HCL)

Study Locations (20)

California

  • USC/Norris Comprehensive Cancer Center — Los Angeles
  • University of California Los Angeles — Los Angeles
  • VA Palo Alto Health Care System — Palo Alto
  • University of California, San Francisco — San Francisco

Illinois

  • Northwestern University — Chicago
  • Northshore University Health System — Evanston

New York

  • NYU Langone's Perlmutter Cancer Center — New York
  • Stony Brook Urology — Stony Brook

Ohio

  • Ohio State University Wexner Medical Center — Columbus
  • Ohio State University — Columbus

Alabama

  • The University of Alabama at Birmingham — Birmingham

Arizona

  • Mayo Clinic — Phoenix

District of Columbia

  • Sibley Memorial Hospital — Washington D.C.

Georgia

  • Emory University School of Medicine — Atlanta

Trial Details

FieldValue
Enrollment Target 4,400 participants
Start Date 2014-04
Est. Completion 2028-12

Sponsor

Photocure

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02660645

The ClinicalTrials.gov registry entry for NCT02660645 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Photocure, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions — of which Karl Storz D-Light C Photodynamic Diagnostic (PDD) system is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02660645 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Illinois, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02660645 about?

NCT02660645 is a clinical study titled "Blue Light Cystoscopy With Cysview® Registry". Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

What is the current status of trial NCT02660645?

This trial is currently recruiting. The enrollment target is 4,400 participants. The study started on 2014-04. Estimated completion is 2028-12.

What conditions does trial NCT02660645 study?

This clinical trial studies the following conditions: Bladder Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02660645?

The interventions under investigation include: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system (DEVICE), Hexaminolevulinate hydrochloride (HCL) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02660645?

This trial is sponsored by Photocure, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02660645 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial